Biocon’s Recipe for Success in the Competitive US Generics Market
Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market. …
Address: 345 Park Avenue
New York, New York
10154
Tel: 800-332-2056
Web: http://www.bms.com/pages/default.aspx
Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Bristol-Myers Squibb produces medicines against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
At Bristol-Myers Squibb, its BioPharma strategy combines a major pharma company with a successful biotech company which helps to focus on the customers’ needs giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.
Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market. …
Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this…
KV Kumar, head of the Indian American International Chamber of Commerce, gives an account of the bilateral trade relations between India and the US and candidly speaks about the opportunities…
Abhijit Zutshi, commercial head global generics & SVP marketing at Indian firm Biocon highlights the challenges inherent in the US generics market, the process of setting up an affiliate in…
Dan Leonard is president & CEO of the National Pharmaceutical Council, which sponsors and participates in research on the appropriate use of pharmaceuticals and the clinical and economic value of…
John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the…
AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic. Like the rest…
Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Barbara Lopez Kunz, CEO of the Drug Information Association (DIA) in the USA, outlines the association’s four key areas of focus – regulatory science, patient engagement, translational science, and value…
Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for…
See our Cookie Privacy Policy Here
